<DOC>
	<DOC>NCT00454883</DOC>
	<brief_summary>Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.</brief_summary>
	<brief_title>Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.</brief_title>
	<detailed_description>Method: Consecutive patient sampling. Patients were included in the study in consecutive manner if they fulfilled the inclusion criteria and any of the exclusion criteria were not present.</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Affective Disorders, Psychotic</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Manic and mixed episodes of up to moderate severity in patients with Type I and II bipolar disorder and schizoaffective disorder; either first diagnosed or repeated episodes Hypersensitivity to ziprasidone prolonged QTc interval coadministration with substances that are prolonging the QTc interval recent acute MI, cardiac failure, patients with arrhythmias treated with class IA or III medicaments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Safety of ziprasidone, efficacy of ziprasidone, manic episodes in bipolar disorder, mixed episodes in bipolar disorder, schizoaffective disorder.</keyword>
</DOC>